General
Preferred name
penicillamine
Synonyms
Dimethyl Cysteine ()
D-Penicillamine ()
Artamine ()
D-(-)-Penicillamine ()
Dimethylcysteine ()
Penicilamina ()
Trolovol ()
Cuprimine ()
D Penicillamine ()
NSC-758421 ()
NSC-81549 ()
D-3-mercaptovaline ()
D Mercaptovaline ()
Distamine ()
Depen ()
Penicillamine-d3 ()
P&D ID
PD009682
CAS
52-67-5
16414-54-3
1113-41-3
771431-20-0
2925655-01-0
Tags
available
drug
nuisance
Approved by
FDA
First approval
1970
Drug indication
Rheumatoid arthritis
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. Penicillamine inhibits macrophages, decreases IL-1 and the number of T-lymphocytes, and prevents collagen cross linkage. In Wilson's disease it binds copper, allowing it to be eliminated in the urine.
DESCRIPTION Penicillamine is a chelating agent and an immunosuppressant. (GtoPdb)
PRICE 29
DESCRIPTION D-Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy. Penicillamine is used as a form of immunosuppression to treat rheumatoid arthritis. (Enamine Bioactive Compounds)
DESCRIPTION Penicillamine (Artamine), possessing antineoplastic properties, induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. Artamine is a beta dimethyl analog of the amino acid cysteine. As a degradation product of penicillin antibiotics, Artamine chelates with heavy metals and increases their urinary excretion. (TargetMol Bioactive Compound Library)
Compound Sets
20
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Nuisance compounds in cellular assays
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
55
Properties
(calculated by RDKit )
Molecular Weight
149.05
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
0
Aromatic Ring Count
0
cLogP
0.11
TPSA
63.32
Fraction CSP3
0.8
Chiral centers
1.0
Largest ring
0.0
QED
0.49
Structural alerts
1
Chelation
Fe
Nuisance compounds
Custom attributes
(extracted from source data)
Target
antibiotic
Copper
Cuproptosis
Drug Metabolite
Indication
Wilson's disease, rheumatoid arthritis, cystinuria
Disease Area
metabolism, rheumatology, nephrology
MOA
chelating agent
Pathway
Microbiology/virology
Apoptosis
Metabolic Enzyme/Protease
Therapeutic Class
Antidotes
Source data